The Extraordinary General Meeting of ChronTech Pharma AB

The Extraordinary General Meeting of ChronTech Pharma AB

 

The Extraordinary General Meeting of ChronTech Pharma AB was held in
Stockholm on November 25, 2011.

The meeting resolved to amend the Articles of Association with regards
to the limits of the maximum and minimum share capital and maximum and
minimal outstanding shares. The resolution means that the share capital
shall amount to a minimum of 5.1 million SEK and a maximum of 20.4
million SEK and also that the number of outstanding shares shall amount
to a minimum of 170 million and a maximum of 680 million.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se (anders.vahlne@ki.se)

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and
ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus
infections, i.e. chronic infections with jaundice causing viruses which
can lead to liver cirrhosis and liver cancer. ChronTech has also
developed and further develops a patent pending new type of injection
needle for a more effective uptake of DNA vaccines. ChronTech also have
part ownership in the wound healing therapy ChronSeal®, and in the new
platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se (http://www.chrontech.se/)

In the event of any discrepancy between the Swedish and English versions
of this press release, the Swedish version will take precedence.